-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Has PD1 Blockade Changed the Standard of Care for cHL?

Program: Education Program
Session: Moving the Needle in Hodgkin Lymphoma
Hematology Disease Topics & Pathways:
Combination therapy, Antibody Therapy, Education, Checkpoint Inhibitor, Treatment Considerations, Biological therapies, Immunotherapy, Monoclonal Antibody Therapy
Saturday, December 7, 2024, 9:30 AM-10:45 AM

Ryan C. Lynch, MD

Fred Hutchinson Cancer Research Center, Seattle, WA

Disclosures: Lynch: SeaGen, Foresight Diagnostics, Abbvie, Janssen: Consultancy; Merck: Honoraria; TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, SeaGen, Rapt, Merck, Janssen: Research Funding.

OffLabel Disclosure: Nivolumab combinations in relapsed CHL Pembrolizumab combinations in relapsed CHL Nivolumab + AVD in untreated Stage 3 or 4 CHL

See more of: Moving the Needle in Hodgkin Lymphoma
See more of: Education Program
Previous Presentation | Next Presentation >>